US20050272652A1
(en)
*
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
DE60134251D1
(de)
|
2000-09-18 |
2008-07-10 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
US7638284B2
(en)
*
|
2000-10-31 |
2009-12-29 |
The Curators Of The University Of Missouri |
Immunoglobulin A inducing protein and uses therefor
|
US7054758B2
(en)
|
2001-01-30 |
2006-05-30 |
Sciona Limited |
Computer-assisted means for assessing lifestyle risk factors
|
EP1432724A4
(de)
*
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
|
GB0205693D0
(en)
*
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
CA2490564A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
US8012454B2
(en)
|
2002-08-30 |
2011-09-06 |
Boston Scientific Scimed, Inc. |
Embolization
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
US7311861B2
(en)
|
2004-06-01 |
2007-12-25 |
Boston Scientific Scimed, Inc. |
Embolization
|
US20060045900A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Robert Richard |
Embolization
|
US7572451B2
(en)
|
2004-10-25 |
2009-08-11 |
Cytos Biotechnology Ag |
Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
EP2390264A1
(de)
|
2005-02-11 |
2011-11-30 |
Amylin Pharmaceuticals Inc. |
GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften
|
US7858183B2
(en)
*
|
2005-03-02 |
2010-12-28 |
Boston Scientific Scimed, Inc. |
Particles
|
US7963287B2
(en)
|
2005-04-28 |
2011-06-21 |
Boston Scientific Scimed, Inc. |
Tissue-treatment methods
|
US20090170762A1
(en)
*
|
2005-09-08 |
2009-07-02 |
Uutech Limited |
Treatment of Diabetes Related Obesity
|
AU2006289259A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US7947368B2
(en)
|
2005-12-21 |
2011-05-24 |
Boston Scientific Scimed, Inc. |
Block copolymer particles
|
AR060406A1
(es)
*
|
2006-04-11 |
2008-06-11 |
Arena Pharm Inc |
Metodos para usar el receptor gpr119 en la identificacion de compuestos utiles para aumentar la masa osea en un individuo
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
MX2009006564A
(es)
|
2007-01-05 |
2009-06-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
|
KR20090119876A
(ko)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
EP2146210A1
(de)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
|
WO2009155257A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
SG192405A1
(en)
|
2008-06-17 |
2013-08-30 |
Univ Indiana Res & Tech Corp |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
PA8830501A1
(es)
|
2008-06-17 |
2010-07-27 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
ES2650621T3
(es)
|
2008-10-17 |
2018-01-19 |
Sanofi-Aventis Deutschland Gmbh |
Combinación de una insulina y un agonista de GLP-1
|
JP2012512903A
(ja)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
|
EP2411038B1
(de)
|
2009-03-27 |
2016-12-28 |
Van Andel Research Institute |
Parathryoidhormonpeptide und parathyroidhormonbezogene proteinpeptide sowie anwendungsverfahren dafür
|
SG176858A1
(en)
|
2009-06-16 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Gip receptor-active glucagon compounds
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含glp-1激動劑及甲硫胺酸之醫藥組成物
|
PE20121362A1
(es)
|
2009-11-13 |
2012-10-17 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
EP2528618A4
(de)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas
|
CN102918027A
(zh)
|
2010-04-06 |
2013-02-06 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与所述受体有关的障碍的治疗
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
EP2569000B1
(de)
|
2010-05-13 |
2017-09-27 |
Indiana University Research and Technology Corporation |
Glucagon-superfamilien-peptide mit nuklearhormon-rezeptoraktivität
|
MX2012014576A
(es)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
MA34885B1
(fr)
|
2010-12-22 |
2014-02-01 |
Indiana Unversity Res And Technology Corp |
Analogues du glucagon presentant una ctivite de recepteur de gip
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
CA2847246A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
CA2877358A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
ES2685987T3
(es)
|
2014-09-05 |
2018-10-15 |
University Of Copenhagen |
Análogos de péptidos gip
|
EP3985016A1
(de)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip-agonisten-verbindungen und -verfahren
|
RS64300B1
(sr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulacija fiksnog odnosa insulin glargina/liksisenatida
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
PE20181327A1
(es)
|
2015-12-23 |
2018-08-20 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
CA3064510A1
(en)
|
2017-05-31 |
2018-12-06 |
University Of Copenhagen |
Long-acting gip peptide analogues
|
BR112019024410A2
(pt)
*
|
2017-06-20 |
2020-07-14 |
Amgen Inc. |
método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
|
WO2019072963A1
(en)
*
|
2017-10-12 |
2019-04-18 |
University Of Copenhagen |
POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES
|
CA3023014C
(en)
*
|
2017-11-06 |
2023-09-26 |
Stalicla Sa |
Pharmaceutical composition for treatment of autism
|
EP3699187A1
(de)
*
|
2019-02-21 |
2020-08-26 |
Universite D'angers |
Peptid zum targeting von gip und glp-2 rezeptoren zur behandlung von knochenerkrankungen
|